Immunomodulators in warts: Unexplored or ineffective?

Sinha, Surabhi; Relhan, Vineet; Garg, Vijay Kumar

doi:10.4103/0019-5154.152502

Cited by 36 publications

(26 citation statements)

References 106 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Discussionmentioning

confidence: 99%

“…Furthermore, in another study, Doan et al27 determined that treatment with green tea extract modulates and downregulates genes involved in the proinflammatory response to HPV infection. In addition, inhibition of HPV binding to receptors as well as signal transduction modification, including inhibition of receptor tyrosine kinases, may add to the pharmacological effect of green tea in Gene-Eden-VIR/Novirin 26,28…”

Section: Discussionmentioning

confidence: 99%

“…Another mechanism of action against HPV involves the inhibition of transcription of HPV viral proteins by antioxidants, including epigallocatechin gallate (EGCG), the lead catechin of green tea. 26 Furthermore, in another study, Doan et al 27 determined that treatment with green tea extract modulates and downregulates genes involved in the proinflammatory response to HPV infection. In addition, inhibition of HPV binding to receptors as well as signal transduction modification, including inhibition of receptor tyrosine kinases, may add to the pharmacological effect of green tea in Gene-Eden-VIR/Novirin.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Human papillomavirus (HPV): systemic treatment with Gene-Eden-VIR/Novirin safely and effectively clears virus

Polansky

Itzkovitz

Javaherian

2017

DDDT

View full text Add to dashboard Cite

PurposeThis paper reports the results of a clinical study that tested the effect of systemic treatment with the botanical product Gene-Eden-VIR/Novirin on the clearance rate (also called time to clearance) of the human papillomavirus (HPV). The study compared the clearance rate in treated and untreated individuals suffering from a symptomatic HPV infection. The data on the untreated individuals were obtained by reverse engineering of the Kaplan–Meier figures in five published papers.Materials and methodsThe study included 59 treated participants. All participants were suffering from a symptomatic HPV infection prior to the commencement of treatment. The treatment was one to four capsules of Gene-Eden-VIR/Novirin per day. The duration of treatment was 2–12 months. The study included five groups of external controls with diverse characteristics.ResultsThe mean time to clearance in Gene-Eden-VIR/Novirin-treated individuals was 5.1 months or 151.5 days (95% CI: 4.2–5.9 months or 95% CI: 125.7–177.3 days, respectively). The median time to clearance was 3.5 months. The mean time to clearance in the five untreated groups ranged from 6.9 to 20.0 months (P<0.0001 for the difference between treatment group and each untreated group). Also, 100% of the participants in the treatment group were HPV free at the end of 12 months vs 53%, 52%, 65%, 20%, and 77% in the untreated control groups. The treated participants reported no adverse experiences.ConclusionThis clinical study has two major contributions. First, it showed that systemic treatment with the natural Gene-Eden-VIR/Novirin decreased the time to HPV clearance, increased the percentage of HPV-free individuals, and caused no adverse experiences in individuals suffering from a symptomatic HPV infection. Since there are no other systemic treatments for symptomatic HPV infections, this study presents highly valuable information on the clinical effects of the first treatment in this category. Second, the study presents a new method for conducting clinical studies that addresses one of the major deficiencies associated with the practice of the randomized controlled trial method.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Human papillomavirus (HPV): systemic treatment with Gene-Eden-VIR/Novirin safely and effectively clears virus

Polansky

Itzkovitz

Javaherian

2017

DDDT

View full text Add to dashboard Cite

show abstract

“…27 DPCP costs approximately $30/session and Imiquimod costs as much as $100/session. SADBE has varying costs but is more unstable and costly than DPCP [28]. DPCP, Imiquimod, and SADBE all may require multiple sessions for a complete response.…”

Section: Comparison Of Costs Of Immunotherapy and Other Therapiesmentioning

confidence: 99%

Wart Immunotherapies: A Short Review

Sefcik¹,

Burkhart²

2017

TODJ

View full text Add to dashboard Cite

Objective:To review the efficacy and costs of various contact immunotherapies, contact allergens, intralesional immunotherapies, and intralesional cytotoxic agents for the treatment of recalcitrant warts. Background:Cutaneous warts are common viral skin lesions caused by human papillomavirus that can be challenging to treat and frustrating for physicians and patients. Although several treatment options exist, there is no single treatment that can ensure a complete response with lack of lesion recurrence. Immunotherapies for recalcitrant warts present as a cost-effective, efficient therapy option for patients. Intralesional approaches have the added benefit of affecting warts at locations distant to the target location by inducing a systemic Tcell mediated response in the body. Results:Various contact immunotherapies, contact allergens, intralesional immunotherapies, and intralesional cytotoxic agents have shown to be effective in treating warts. The costs of each treatment varies drastically from around $10 US to over $1000 US to achieve a complete response. Several antigens were found to be both efficacious and cost effective. Conclusion:Although efficacy of several antigens has been confirmed by randomized studies, more randomized comparative studies will need to be performed in order to determine the best antigen and correct standardized doses for the treatment of warts in individual patients. It is important to note that individual response to antigen type and dose may vary among patients. Therefore, further studies may play an important role in the use of immunotherapies in a clinical setting.

show abstract

“…All the forms of treatment, when well prescribed and adequately applied produce good results and have similar efficacy 4 . The rates of recurrence vary from 30-70% [5][6][7] , and have significant psychological impact on both the patient and their family members. With a view to reducing the recurrence rate, many agents have been used as stimulators of local immunity 6,8 .…”

Section: Introductionmentioning

confidence: 99%

BCG In the treatment of recurrent. Genital condyloma accuminatum

Chen

Lucon

2018

Rev. Med. (São Paulo)

View full text Add to dashboard Cite

Introduction: The Human Papilloma Virus (HPV) is the most prevalent sexually transmissible disease. The treatment of Condyloma Accuminatum is a great challenge because of the high recurrence rate and of the lack of any drug efficient in its elimination. Objective: To assess the efficacy of the treatment with Imuno BCG (Bacillus Calmette-Guérin) for bearers of condylomas recurrent for more than 2 years. Patients and Methods: Patients with age between 18 and 60 years, having a history of more than 2 years of genital warts, were included, attended as from 01-08-2011; bearers of serious diseases, immunodeficiency or users of immune-suppressors, being excluded. The procedure adopted began with a biopsy of the wart(s) with local anesthetic, followed by the electro-coagulation of all the warts and bases of the biopsies, a solution with 80 mg of Imuno BCG dissolved in 2 ml of saline solution 0.9% was applied to all the genital area, including the cauterized areas. The area was covered with plastic for 2 hours and afterwards washed with water. The local application of Imuno BCG was repeated for 8 consecutive weeks. At the end of the second month the cases were re-assessed. When there was clinical recurrence a new procedure with the same drug was undertaken, but with 3 weekly applications made by the patient himself for 8 weeks. Result: Sixteen patients completed 2-year follow-up. The cure rate was of 62.5%. Of the 10 patients cured, 6 (37.5%) used one series of Imuno BCG, 1 (6.25%) used 2 series, and 3 (18.75%) used 3 series. Of the 6 patients who were not cured, there was a reduction in the number of cauterizations from 5.5 times (over an average period of the disease of 51.6 months) to 2.4 cauterizations (over an average follow-up period of 52.3 months) after the use Imuno BCG. The collateral effects of the use of Imuno BCG were insignificant. Conclusion: Topical BCG is a good option for the treatment of recurrent condylomas, with minimal collateral effect. It may be used even on PPD-negative patients. However, this result must be confirmed with larger sample populations and control-group studies.

show abstract

Immunomodulators in warts: Unexplored or ineffective?

Cited by 36 publications

References 106 publications

Human papillomavirus (HPV): systemic treatment with Gene-Eden-VIR/Novirin safely and effectively clears virus

Human papillomavirus (HPV): systemic treatment with Gene-Eden-VIR/Novirin safely and effectively clears virus

Wart Immunotherapies: A Short Review

BCG In the treatment of recurrent. Genital condyloma accuminatum

Contact Info

Product

Resources

About